ADV-110 is under clinical development by Beijing Advaccine Biotechnology and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase II drugs for Respiratory Syncytial Virus (RSV) Infections have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ADV-110’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADV-110 is under development for the prevention of respiratory syncytial virus infection. It is a recombinant respiratory syncytial virus (rRSV) vaccine and is administered through intramuscular route.is under development for the prevention of respiratory syncytial virus infection. It is a recombinant respiratory syncytial virus (rRSV) vaccine and is administered through intramuscular route.
Beijing Advaccine Biotechnology overview
Beijing Advaccine Biotechnology, a biotechnology company that focused on discovery of new vaccines. The company is headquartered in China.
For a complete picture of ADV-110’s drug-specific PTSR and LoA scores, buy the report here.